

PROPRIETARY INFORMATION/FOIA EXEMPT
WITHHOLD FROM PUBLIC DISCLOSURE UNDER 10 CFR 2.390
Upon the removal of Enclosure (1) this document can be made public

John R. Jolicoeur
Acting Deputy Director
Division of Policy and Rulemaking
Office of Nuclear Reactor Regulation
U.S. Nuclear Regulatory Commission
Washington, DC 20555-0001

February 28, 2011

SUBJECT: Coquí Radiopharmaceuticals Corp.'s Response to NRC Request for Planned Milestones

REFERENCE: (a) January 21, 2011 Letter from John Jolicouer (NRC) to Mark Geurts (Coquí) re: Request for Planned Milestones

As requested in Reference (a), Coquí Radiopharmaceuticals Corp. (Coquí) is providing the Nuclear Regulatory Commission (NRC) herein with scheduling information pertaining to its proposed Medical Isotope Production Facility (MIPF). This response serves to supplement Coquí's March 15, 2010 letter of intent (ML100820170) as well as other scheduling communications made to the NRC, including during Coquí's October 6, 2010 NRC public meeting.

Because Coquí considers the information contained in Enclosure (1) to be proprietary, Coquí requests that Enclosure (1) be withheld from public disclosure, pursuant to 10 CFR § 2.390 and § 9.17(a)(4). We have provided the necessary affidavit to support our request in Enclosure (3). We have also provided a public version of our response in Enclosure (2). Upon the removal of Enclosure (1), this document can be made public.

PROPRIETARY INFORMATION/FOIA EXEMPT
WITHHOLD FROM PUBLIC DISCLOSURE UNDER 10 CFR 2.390
Upon the removal of Enclosure (1) this document can be made public

If you have questions or need additional information, please contact me at 787.993.2806 or by email at mgeurts@coquipharma.com.

Sincerely,



Mark Geurts
Chief Operating Officer
Coquí Radiopharmaceuticals Corp.

Enclosure: (1) Coquí Radiopharmaceuticals Corp. Scheduling Update (Proprietary Version)

 (2) Coquí Radiopharmaceuticals Corp. Scheduling Update (Public Version)

 (3) 10 CFR 2.390 Affidavit of Mark Geurts, Chief Operating Officer, Coquí
 Radiopharmaceuticals Corp.

Cc: Mary Jane Ross-Lee, NRC
 Ossy Font, NRC
 Marcus Voth, NRC
 Amy C. Roma, Hogan Lovells US LLP
 Alejandro J. Valderrábano-Wagner, Fiddler Gonzalez & Rodriguez, P.S.C.